Intercept Pharmaceuticals to Conduct One-on-One Meetings with Investors at the Barclays Global Healthcare Conference March 14, 2023
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) announced its participation in the Barclays Global Healthcare Conference on March 14, 2023, at the Loews Miami Beach Hotel.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) announced its participation in the Barclays Global Healthcare Conference on March 14, 2023, at the Loews Miami Beach Hotel. This conference provides an opportunity for investors to engage with the Intercept management team, enhancing its visibility in the healthcare sector. Intercept focuses on innovative therapeutics for progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). The company encourages interested investors to connect for potential meetings with its management team.
Positive
- Participation in the Barclays Global Healthcare Conference may attract investor interest.
- Opportunity for management to engage directly with potential investors.
Negative
- None.
Details
News Market Reaction – ICPT
The recorded move for ICPT in the trading session of this news was -3.60%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MORRISTOWN, N.J., March 09, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it will be participating in investor meetings at the Barclays Global Healthcare Conference at the Loews Miami Beach Hotel on March 14, 2023.
Meeting Details
For investors attending the conference who wish to meet with the Intercept management team, please reach out to Nareg Sagherian at Intercept to check the team’s availability.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH) and severe alcohol-associated hepatitis (sAH). For more information, please visit www.interceptpharma.com or connect with the Company on Twitter and LinkedIn.
Contact
For more information about Intercept, please contact:
Investor inquiries: investors@interceptpharma.com
Media inquiries: media@interceptpharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.